Domestic Correspondence.

International dental journal (Philadelphia, Pa.) · March 1890

What this study found

This study examines Domestic Correspondence. Editorial review is required before publishing clinical takeaways.

Open on PubMed

SELECT landmark

Why this trial matters

SELECT semaglutide obesity CVOT

How RAGMD uses this study

Clinical questions this paper informs

Synthesis lives on the evidence question — this page shows where the study sits in that analysis.

Supporting literature

Do GLP-1 receptor agonists reduce major cardiovascular events?

GLP-1 receptor agonists with cardiovascular outcome trials (including liraglutide and semaglutide in selected populations) reduce major adverse cardiovascular events beyond glucose lowering in high-risk patients with type 2 diabetes or obesity.

Open evidence analysis

Read the evidence analysis Research library